Miyauchi M, Endo R, Hisaoka M, Yasuda H, Kawamoto I
Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
J Antibiot (Tokyo). 1997 May;50(5):429-39. doi: 10.7164/antibiotics.50.429.
We have studied an ester prodrug of a carbapenem to develop a potent orally active beta-lactam antibiotic. A variety of 1 beta-methylcarbapenem derivatives have been synthesized. We have found that some derivatives having an amide group in the C-2 side chain show potent and well balanced antibacterial activities as well as high stability against dehydropeptidase-I. Oral absorption of derivatives has been optimized by modifying the C-3 ester promoiety. Pivaloyloxymethyl (1R, 5S, 6S)-6-[(R)-1-hydroxyethyl]-l-methyl-2-[(R)-5-oxopyrrolidin-3-yl thio]- l-carbapen-2-em-3-carboxylate, CS-834, has been selected as the most promising compound for further evaluation.
我们研究了一种碳青霉烯酯前药,以开发一种强效的口服活性β-内酰胺抗生素。已经合成了多种1β-甲基碳青霉烯衍生物。我们发现,一些在C-2侧链带有酰胺基团的衍生物显示出强效且平衡良好的抗菌活性,以及对脱氢肽酶-I的高稳定性。通过修饰C-3酯部分优化了衍生物的口服吸收。新戊酰氧甲基(1R,5S,6S)-6-[(R)-1-羟乙基]-1-甲基-2-[(R)-5-氧代吡咯烷-3-基硫代]-1-碳青霉-2-烯-3-羧酸酯,CS-834,已被选为最有前景的化合物进行进一步评估。